Autolus Therapeutics (AUTL)
NASDAQ:AUTL
Want to see AUTL full AI Analyst Report?
Total Valuation
Autolus Therapeutics has a market cap or net worth of $497.71M. The enterprise value is $446.72M.
Market Cap$497.71M
Enterprise Value$446.72M
Share Statistics
Autolus Therapeutics has 266,155,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding266,155,800
Owned by Insiders―
Owned by Institutions40.45%
Financial Efficiency
Autolus Therapeutics’s return on equity (ROE) is -1.62 and return on invested capital (ROIC) is -51.54%.
Return on Equity (ROE)-1.62
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-51.54%
Return on Capital Employed (ROCE)-0.55
Revenue Per Employee116.79K
Profits Per Employee-444.40K
Employee Count647
Asset Turnover0.13
Inventory Turnover2.91
Valuation Ratios
The current PE Ratio of Autolus Therapeutics is ―. Autolus Therapeutics’s PEG ratio is -0.08.
PE Ratio―
PS Ratio7.01
PB Ratio2.97
Price to Fair Value2.97
Price to FCF-1.75
Price to Operating Cash Flow-1.79
PEG Ratio-0.08
Income Statement
In the last 12 months, Autolus Therapeutics had revenue of 75.56M and earned -288.20M in profits. Earnings per share was -1.08.
Revenue75.56M
Gross Profit-21.03M
Operating Income-281.44M
Pretax Income-296.85M
Net Income-288.20M
EBITDA-271.60M
Earnings Per Share (EPS)-1.08
Cash Flow
In the last 12 months, operating cash flow was -273.32M and capital expenditures -18.20M, giving a free cash flow of -291.52M billion.
Operating Cash Flow-273.32M
Free Cash Flow-291.52M
Free Cash Flow per Share-1.10
Dividends & Yields
Autolus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.48
52-Week Price Change-11.11%
50-Day Moving Average1.53
200-Day Moving Average1.54
Relative Strength Index (RSI)62.49
Average Volume (3m)1.57M
Important Dates
Autolus Therapeutics upcoming earnings date is Jul 30, 2026, Before Open (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Autolus Therapeutics as a current ratio of 5.94, with Debt / Equity ratio of 73.47%
Current Ratio5.94
Quick Ratio5.48
Debt to Market Cap0.54
Net Debt to EBITDA-0.91
Interest Coverage Ratio-7.66
Taxes
In the past 12 months, Autolus Therapeutics has paid -8.65M in taxes.
Income Tax-8.65M
Effective Tax Rate0.03
Enterprise Valuation
Autolus Therapeutics EV to EBITDA ratio is -2.86, with an EV/FCF ratio of -2.56.
EV to Sales10.28
EV to EBITDA-2.86
EV to Free Cash Flow-2.56
EV to Operating Cash Flow-2.74
Balance Sheet
Autolus Therapeutics has $229.43M in cash and marketable securities with $79.96M in debt, giving a net cash position of $149.48M billion.
Cash & Marketable Securities$229.43M
Total Debt$79.96M
Net Cash$149.48M
Net Cash Per Share$0.56
Tangible Book Value Per Share$0.59
Margins
Gross margin is -11.19%, with operating margin of -372.45%, and net profit margin of -381.40%.
Gross Margin-11.19%
Operating Margin-372.45%
Pretax Margin-392.84%
Net Profit Margin-381.40%
EBITDA Margin-359.43%
EBIT Margin-372.45%
Analyst Forecast
The average price target for Autolus Therapeutics is $8.08, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.08
Price Target Upside405.00% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast928.46%
EPS Growth Forecast-21.39%